Editorial Board

A. Seth
Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada

J.G. Delinassios
Managing Editor and Executive Publisher,
International Institute of Anticancer Research, Athens, Greece

L.A. Aaltonen
Department of Medical Genetics, University of Helsinki, Finland

S. Aaronson
Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA

R. Abagyan
The Scripps Research Institute, La Jolla, CA, USA

J.D. Aitchison
Institute for Systems Biology, Seattle, WA, USA

W. Ansorge
IAET, Borex, Switzerland

S. Antonarakis
Division of Medical Genetics, University of Geneva Medical School, Switzerland

F.G. Barr
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

A.M. Burger
Department of Pharmacology and Experimental Therapeutics, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA

A.M. Chinnaian
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

B.F.C. Clark
Department of Molecular Biology, University of Aarhus, Denmark

R. Clarke
Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA

I. Dunham
The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK

N.A. Ellis
Department of Medicine University of Chicago, IL, USA

J.A. Fernandes-Pol
Metalloproteomics, LLC, Chesterfield, MO, USA

C.V. Forst
McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA

M. Fouontoulakis
F. Hoffman - La Roche Pharmaceutical Research, Basel, Switzerland

W.L. Gerald
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

J.W. Gray
Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA

B.B. Haab
Van Andel Research Institute, Grand Rapids, MI, USA

C.-H. Heldin
Ludwig Institute for Cancer Research, Uppsala, Sweden

J.D. Hoheisel
Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany

R.P. Huang
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA

T.H.M. Huang
Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA

Y. Ito
Institute of Molecular and Cell Biology, Oncology Research Institute, Yon Loo Lin School of Medicine, National University of Singapore, Singapore

V.C. Jordan
Fox Chase Cancer Center, Philadelphia, PA, USA

A. Kallioniemi
Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland

O.P. Kallioniemi
Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland

M. Kanehisa
Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan

S.E. Kern
Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA

K. Khalili
College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA

S.D. Kottaridis
Department of Virology, Hellenic Anticancer Institute, Athens, Greece

B. Leyland-Jones
Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA

P. Lichter
Deutsches Krebsforschungszentrum, Heidelberg, Germany

A. Lindblom
Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden

G. Lubec
Department of Pediatrics, University of Vienna, Austria

N. Lyons-Weiler
Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA

P.J. McCormick
Center for Comp. Functional Genomics, VA Medical Center University at Albany, SUNY, Rensselaer, NY, USA

J.D. Minna
Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA

F. Mitelman
Department of Clinical Genetics, University Hospital, Lund, Sweden

P. Nelson
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

C. Nicot
Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA

L. O’Driscoll
National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
Contents

* Collagen – A Necessary Accomplice in the Metastatic Process. P.S. NERENBERG, R. SALSAS-ESCAT, C.M.
STULTZ (Cambridge, MA, U.S.A.) ................................................................. 319

Differential Expression of Ribosomal Proteins in a Human Metastasis Model Identified by Coupling 2-D Liquid
Chromatography and Mass Spectrometry. P. KREUNIN, C. YOO, V. URQUIDI, D.M. LUBMAN, S.
GOODISON (Michigan; Ann Arbor, MI; Jacksonville, FL, U.S.A.) .................... 329

17HSD 2 may be Higher in African-American Breast Cancer and is Associated with Estrogen Receptor-negative
Tumors. R. YAEGGER, P.C. NOLAN, T. SU, A. AVILA-BRONT, X. WANG, Y.-K. K. CHEUNG, H. LIU,

* Molecular Profiling for the Identification of New Biomarkers in Smokers and Cancer Patients. K.
ALBERMANN, S. LANG, R. ZEIDLER (Essen; Munich, Germany) ......................... 349

Genome-wide Expression Profiling Reveals New Insights into Pathogenesis and Progression of Testicular Germ
Cell Tumors. K. BIERMANN, L.S.C. HEUKAMP, K. STEGER, H. ZHOU, F.E. FRANKE, V. SONNACK,
R. BREHM, J. BERG, P.J. BASTIAN, S.C. MÜLLER, L. WANG-ECKERT, R. BUETTNER (Bonn;
Giessen; Cologne, Germany) ............................................................................. 359

Activity of the Glutathione Peroxidase-2. Differences in the Selenium-dependent Expression between Colon and
KYRIAKOPOULOS (Berlin; Teltow, Germany) .................................................... 369

Errata .................................................................................................................. 373

* Reviews (pages 319, 349)
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated in confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

Copyright. On publication of a manuscript in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 200 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements and (b) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.


Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J.G. Delinassios, Managing Editor, Cancer Genomics and Proteomics, International Institute of Anticancer Research, 1st km Kapanidritou-Kalamou Rd., Kapanidriti, P.O. Box 22, Attiki 19014, Greece. A CD-ROM, floppy disc, or ZIP-disc should also be submitted indicating the computer-processing program. Additionally, for speed of processing, manuscripts may be sent by e-mail to www.cgp-journal.com. Authors are invited to submit, along with their manuscripts, a short list of possible reviewers and any previous publications which could facilitate reviewing. Only the original copy of the submitted manuscript will be returned to the Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.